10 October 2019

KWF roadshow: Monday 11 November 2019, 11:30 - 14:00 hrs. 
Location: Tuinzaal, route 706
Registration: required by acceptance of the Outlook invitation



In which way(s) can KWF provide optimal support to oncological research and care? How can we maximize impact on our investments? These questions are pivotal in Ambition 2030: the vision that KWF developed in close cooperation with stakeholders in the oncological field.

The dialogue session covers the topics:

  • 9 new keystone initiatives
  • guidelines for writing research grants
  • changes in the KWF funding conditions
The dialogue session will be visited by a delegation of KWF programme coordinators. They are available for further questions after the sessions. The dialogue sessions are highly recommendable for researchers, as well as clinicians, pharmacists and other ‘research-minded’ colleagues. 

Program:
11:30   Ambition 2030 explained
             From research call to implementation
12:15   Lunch break 
12:45   New funding conditions
             Collaborating: now and in the future
13:30   Discussion

 

Related news items


1.5 million euro grant for research into earlier recognition of Parkinson's disease

27 October 2021

Researchers aim to improve identification of early symptoms and subtypes of Parkinson's disease with large international study

read more

BRAINMODEL: precision medicine for brain disorders

25 October 2021

A team of researchers from Radboudumc, VU Amsterdam and other institutes is going to look for new and better ways to heal developmental disorders in the brain.

read more

How healthy is James Bond? - A flu to a kill No time to die: the pathogens surrounding secret agent 007

21 October 2021

James Bond made a total of 25 films between 1962 and 2021. In all those films, secret agent 007 washed his hands only twice, even though he often stayed in not so hygienic places with considerable health risks. Radboudumc researchers examined all the health risks in the 47 countries Bond visited.

read more

Surprisingly dominant cause underlying type I congenital defect of glycosylation

21 October 2021

Alex Garanto, Melissa Bärenfänger, Mirian Janssen, and Dirk Lefeber published a new study, identifying a surprisingly dominant genetic cause underlying type I congenital defect of glycosylation with neuromusculoskeletal phenotypes.

read more

Sensitive blood-test as a patient-friendly alternative for bone marrow-based cancer monitoring

20 October 2021

Hans Jacobs and Pieter Langerhorst, theme Cancer development and immune defense, and colleagues are one step closer to implementation of personalized diagnostics for bone marrow-based cancer monitoring.

read more